



Investigating the Characteristics of Cutaneous T Cells in Systemic Sclerosis and Atopic Dermatitis Using Single-cell RNA Sequencing Data



Casey Stein, MD, Lais Osmani, MD, Sang Jin Lee, MD, and Insoo Kang, MD
Department of Internal Medicine, Yale School of Medicine, New Haven, CT

Background

- Single-cell RNA sequencing (scRNA-seq) has allowed for the high-resolution characterization of T cells, providing new insights into their gene expression patterns and plasticity.
- T cells, a key immune regulator, are a complex and heterogeneous population that can be classified into different subsets based on the expression of cell surface molecules, effector molecules, and transcription factors.
- T cells play an important role in the development of many different disorders, including systemic sclerosis (SSc).
- SSc is a systemic autoimmune disease with high morbidity and mortality and a paucity of good therapeutic options.
- Although there is some evidence supporting the role of a type 2-oriented response in SSc, it is not clear whether T cells in systemic sclerosis have the same characteristics as those found in classic type 2-driven diseases such as atopic dermatitis (AD).

Objective


- Investigate the gene expression profile of T cells in systemic sclerosis as compared to atopic dermatitis using publicly available scRNA-seq data.

Question



- Are there similarities in the characteristics of T cells in SSc and AD that could support shared therapeutic strategies specific for T cell-mediated inflammation and tissue damage?
- For example, dupilumab, a monoclonal antibody which blocks the binding of the type 2 cytokines IL-4 and IL-13 to their receptor, is currently used to treat AD.

Methods

- scRNA-seq analysis can be used to investigate cellular heterogeneity and transcriptional similarities and differences within a population of cells at the single cell level.
- This project used publicly available scRNA-seq datasets, one for atopic dermatitis (5 patients with AD, 7 healthy controls) and one for SSc (55 patients with SSc, 21 healthy controls), to compare T cell profiles in skin samples.
- The datasets were analyzed using R-based platforms, including the Seurat package.
- For each dataset, a quality control workflow was used to remove low-quality cells. The data was normalized and scaled to allow for cell clustering based on transcriptomic profiles.
- Due to differences between the AD and SSc experimental datasets, these datasets were analyzed separately in R.




- Biased and unbiased approaches were used to examine and identify clusters.





Results

- In the AD data, there were two T cell clusters that showed notable expansion in lesional atopic dermatitis samples as compared to healthy samples.



- Both clusters had increased expression of *CD8*, type 2 cytokines, and cytotoxic molecules, although each cluster had a slightly different profile.



Results (continued)

- In the SSc data, the cluster with the highest expression of *CD8* was found in similar percentages in both controls and in patients with SSc. This cluster expressed relatively high levels of cytotoxic molecules such as *GZMB* but not type 2 cytokines such as *IL13*. Also in the SSc dataset, a T cell cluster with comparatively high levels of *CD4* and the type 2 response master regulator *GATA3* modestly expanded in SSc as compared to healthy controls.

Limitations

- This was a limited analysis given the following:
 - Small sample sizes in the AD data
 - Inherent differences between the atopic dermatitis and SSc experiments/datasets
 - Due to the differences between the SSc and AD datasets, the two datasets were analyzed separately in R, therefore allowing for only a qualitative comparison of the two diseases.

Conclusions

- Based on the above limited analysis, lesional CD8+ T cells in AD appear somewhat different than those in SSc.
- In comparison to AD, CD8+ T cells with *IL13* expression in SSc skin appear to be less frequent. However, given the above limitations, further research will be needed to see if this conclusion holds in future studies.

References

Gur C, Wang SY, Sheban F, Zada M, Li B, Kharouf F, Peleg H, Aamar S, Yalin A, Kirschenbaum D, Braun-Moscovici Y, Jaitin DA, Meir-Salame T, Hagai E, Kragestein BK, Avni B, Grisariu S, Bornstein C, Shlomi-Loubaton S, David E, Shreberk-Hassidim R, Molho-Pessach V, Amar D, Tzur T, Kuint R, Gross M, Barbov O, Moshe A, Fellus-Alyagor L, Hirsch D, Addadi Y, Erenfeld S, Biton M, Tzemach T, Elazary A, Naparstek Y, Tzemach R, Weiner A, Giladi A, Balbir-Gurman A, Amit I. LGR5 expressing skin fibroblasts define a major cellular hub perturbed in scleroderma. *Cell*. 2022 Apr 14;185(8):1373-1388.e20. doi: 10.1016/j.cell.2022.03.011. Epub 2022 Apr 4. PMID: 35381199; PMCID: PMC7612792.

He H, Suryawanshi H, Morozov P, Gay-Mimbrera J, Del Duca E, Kim HJ, Kameyama N, Estrada Y, Der E, Krueger JG, Ruano J, Tuschi T, Guttman-Yassky E. Single-cell transcriptome analysis of human skin identifies novel fibroblast subpopulation and enrichment of immune subsets in atopic dermatitis. *J Allergy Clin Immunol*. 2020 Jun;145(6):1615-1628. doi: 10.1016/j.jaci.2020.01.042. Epub 2020 Feb 7. PMID: 3203598